Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takemasa Tsuji

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Oncoimmunology|June 28, 2012
Split T-cell tolerance as a guide for the development of tumor antigen-specific immunotherapyTakemasa Tsuji, Sacha Gnjatic
Plos One|November 8, 2014
Differential antigen expression profile predicts immunoreactive subset of advanced ovarian cancersKevin H Eng, Takemasa Tsuji
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancerEmese Zsiros, Takemasa Tsuji, Kunle Odunsi
Cancer Cell|May 10, 2022
Tissue residency of memory CD8<sup>+</sup> T cells matters in shaping immunogenicity of ovarian cancerTakemasa Tsuji, Junko Matsuzaki, Kunle Odunsi
Oncoimmunology|January 10, 2022
Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancerJunko Matsuzaki, Shashikant Lele, Kunle Odunsi, et al.
Genes & Cancer|December 2, 2015
Immuno-stimultory/regulatory gene expression patterns in advanced ovarian cancerKevin H Eng, Isabelle Weir, Takemasa Tsuji, et al.
Autoimmunity|October 18, 2005
Immunosteroid as a regulator for Th1/Th2 balance: its possible role in autoimmune diseasesJunko Matsuzaki, Takemasa Tsuji, Ikuo Imazeki, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 8, 2009
Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccinationTakemasa Tsuji, Nasser K Altorki, Gerd Ritter, et al.
Cellular Immunology|November 12, 2003
Successful elimination of memory-type CD8+ T cell subsets by the administration of anti-Gr-1 monoclonal antibody in vivoJunko Matsuzaki, Takemasa Tsuji, Kenji Chamoto, et al.
Journal for Immunotherapy of Cancer|January 11, 2019
A rare population of tumor antigen-specific CD4<sup>+</sup>CD8<sup>+</sup> double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cellsJunko Matsuzaki, Takemasa Tsuji, Thinle Chodon, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Oncoimmunology|June 28, 2012
Split T-cell tolerance as a guide for the development of tumor antigen-specific immunotherapyTakemasa Tsuji, Sacha Gnjatic
Plos One|November 8, 2014
Differential antigen expression profile predicts immunoreactive subset of advanced ovarian cancersKevin H Eng, Takemasa Tsuji
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancerEmese Zsiros, Takemasa Tsuji, Kunle Odunsi
Cancer Cell|May 10, 2022
Tissue residency of memory CD8<sup>+</sup> T cells matters in shaping immunogenicity of ovarian cancerTakemasa Tsuji, Junko Matsuzaki, Kunle Odunsi
Oncoimmunology|January 10, 2022
Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancerJunko Matsuzaki, Shashikant Lele, Kunle Odunsi, et al.
Genes & Cancer|December 2, 2015
Immuno-stimultory/regulatory gene expression patterns in advanced ovarian cancerKevin H Eng, Isabelle Weir, Takemasa Tsuji, et al.
Autoimmunity|October 18, 2005
Immunosteroid as a regulator for Th1/Th2 balance: its possible role in autoimmune diseasesJunko Matsuzaki, Takemasa Tsuji, Ikuo Imazeki, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 8, 2009
Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccinationTakemasa Tsuji, Nasser K Altorki, Gerd Ritter, et al.
Cellular Immunology|November 12, 2003
Successful elimination of memory-type CD8+ T cell subsets by the administration of anti-Gr-1 monoclonal antibody in vivoJunko Matsuzaki, Takemasa Tsuji, Kenji Chamoto, et al.
Journal for Immunotherapy of Cancer|January 11, 2019
A rare population of tumor antigen-specific CD4<sup>+</sup>CD8<sup>+</sup> double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cellsJunko Matsuzaki, Takemasa Tsuji, Thinle Chodon, et al.
Pageof 6